Dopamine agonists

被引：41

作者：

Factor, SA ^{[1
]}

机构：

[1] Albany Med Coll, Albany Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorder Ctr, Albany, NY 12203 USA

来源：

MEDICAL CLINICS OF NORTH AMERICA | 1999年 / 83卷 / 02期

关键词：

D O I：

10.1016/S0025-7125(05)70112-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole. These agents differ in dopamine receptor affinities and chemical structure, which, in turn, may possibly result in differences in efficacy tolerability and safety. Dopamine have historically been used in combination with levodopa in patients with advanced PD, but indicators are now expanding. With is expansion comes increasing controversy. This article reviews dopamine receptor pharmacology and the results of the clinical trials that have used for agonists available in the United States as well as a discussion of three minor agonists.

引用

页码：415 / +

页数：31

共 95 条

[1] Ropinirole for the treatment of early Parkinson's disease [J].